Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

5.090 -0.130 (-2.49%)
Streaming Delayed Price Updated: 12:48 PM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Earnings Scheduled For May 22, 2025 ↗
 
Via Benzinga
News headline image
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
From Replimune Group Inc
Via GlobeNewswire
News headline image
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates ↗
 
Via Benzinga
News headline image
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
PDUFA action date of July 22, 2025, with priority review 
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces Pricing of Upsized Public Offering
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces Proposed Public Offering
From Replimune Group Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views ↗
 
Via Benzinga
News headline image
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Dow Jumps 300 Points; Gap Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
News headline image
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Replimune Group Inc
Via GlobeNewswire
News headline image
REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025 ↗
REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.